The Company has received the resolution from the Data Monitoring Committee (DMC) regarding the interim safety data review for its ongoing Phase II clinical trial of childhood myopia.

The Committee unanimously concluded that the current participant safety data is favorable, with no modifications to the trial design required.

Accordingly, the DMC has formally recommended that the trial proceed as originally planned.

This resolution demonstrates the robustness and safety of the Company’s novel myopia treatment.

We will continue to advance the clinical trial process as scheduled.